Georgina Long, BSc, PhD, MBBS, FRACP is a clinical researcher and Medical Oncologist at Melanoma Institute Australia and Westmead Hospital, University of Sydney, Australia. She was a Fulbright Postdoctoral Scholar at Scripps Research Institute. She is an investigator on Phase I, II and III clinical trials in adjuvant and metastatic melanoma, and, with her colleagues at Westmead, spear-headed the investigation of BRAF inhibitor activity in the brain. She is chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular focus on clinical and biomarker correlates of systemic therapy sensitivity and resistance. Since commencing at Melanoma Institute Australia in 2009, she has authored multiple publications in clinical and translational research in melanoma, and is a regular invited speaker at international conferences.